ES2521596T3 - Combinación del compuesto GlyT1 con antipsicóticos - Google Patents

Combinación del compuesto GlyT1 con antipsicóticos Download PDF

Info

Publication number
ES2521596T3
ES2521596T3 ES11739097.1T ES11739097T ES2521596T3 ES 2521596 T3 ES2521596 T3 ES 2521596T3 ES 11739097 T ES11739097 T ES 11739097T ES 2521596 T3 ES2521596 T3 ES 2521596T3
Authority
ES
Spain
Prior art keywords
alkyl
halogen
substituted
glyt1
antipsychotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11739097.1T
Other languages
English (en)
Inventor
Daniela Alberati
Jean-Luc Moreau
Joseph G. Wettstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2521596(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2521596T3 publication Critical patent/ES2521596T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Combinación farmacéutica que comprende un fármaco antipsicótico atípico y un antagonista de receptor de GlyT1 de fórmula:**Fórmula** en la que: Ar es un grupo heteroarilo de 6 elementos sustituido que contiene uno, dos o tres átomos de nitrógeno, y en el que los grupos heteroarilo pueden sustituirse con uno o más sustituyentes seleccionados de entre el grupo que consiste de halógeno, alquilo C1-C6 o alquilo C1-C6 sustituido con halógeno, R1 es hidrógeno o alquilo C1-C6, R2 es alquilo C1-C6 sustituido con halógeno, R3, R4 y R6 son, independientemente entre sí, hidrógeno, halógeno, alquilo C1-C6 o alcoxi C1-C6, R5 es SO2R10, R10 es alquilo C1-C6 sustituido opcionalmente con halógeno, o sales de adición de ácido farmacéuticamente aceptables de los mismos, así como formas enantioméricas de los mismos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8

Claims (1)

  1. imagen1
    imagen2
ES11739097.1T 2010-08-09 2011-08-05 Combinación del compuesto GlyT1 con antipsicóticos Active ES2521596T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10172316 2010-08-09
EP10172316 2010-08-09
PCT/EP2011/063533 WO2012019970A1 (en) 2010-08-09 2011-08-05 Combination of glyt1 compound with antipsychotics

Publications (1)

Publication Number Publication Date
ES2521596T3 true ES2521596T3 (es) 2014-11-13

Family

ID=44512856

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11739097.1T Active ES2521596T3 (es) 2010-08-09 2011-08-05 Combinación del compuesto GlyT1 con antipsicóticos

Country Status (29)

Country Link
US (1) US20120035156A1 (es)
EP (1) EP2603219B1 (es)
JP (1) JP2013533297A (es)
KR (1) KR101455947B1 (es)
CN (1) CN103068388A (es)
AR (1) AR084401A1 (es)
AU (1) AU2011288536B2 (es)
BR (1) BR112013003068A2 (es)
CA (1) CA2803656A1 (es)
CL (1) CL2013000378A1 (es)
CR (1) CR20130027A (es)
CY (1) CY1115886T1 (es)
DK (1) DK2603219T3 (es)
EA (1) EA201291477A1 (es)
EC (1) ECSP13012431A (es)
ES (1) ES2521596T3 (es)
HR (1) HRP20141199T1 (es)
MA (1) MA34457B1 (es)
MX (1) MX2013001166A (es)
NZ (1) NZ604891A (es)
PE (1) PE20131100A1 (es)
PH (1) PH12013500078A1 (es)
PL (1) PL2603219T3 (es)
PT (1) PT2603219E (es)
SG (1) SG187108A1 (es)
SI (1) SI2603219T1 (es)
TW (1) TW201211019A (es)
WO (1) WO2012019970A1 (es)
ZA (1) ZA201300434B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230747T1 (hr) 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
CA2924016A1 (en) * 2013-12-03 2015-06-11 F. Hoffmann-La Roche Ag Pharmaceutical composition
CN106687626B (zh) * 2014-04-30 2021-01-26 宇凤·简·曾 作为d-氨基酸氧化酶抑制剂的已知化合物的用途
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SG11201702799UA (en) * 2014-10-07 2017-05-30 Sage Therapeutics Inc Neuroactive compounds and methods of use thereof
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MX382122B (es) 2015-07-06 2025-03-13 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
PL3319611T3 (pl) 2015-07-06 2021-07-12 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PT3519422T (pt) 2016-09-30 2022-12-05 Sage Therapeutics Inc Oxisteróis substituídos em c7 e métodos como moduladores nmda
DK4105223T3 (da) 2016-10-18 2025-07-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
MX2020004975A (es) * 2017-11-14 2020-08-24 Sk Biopharmaceuticals Co Ltd Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia.
KR20220125326A (ko) * 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53252B (sr) * 2003-08-11 2014-08-29 F.Hoffmann-La Roche Ag. Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
ES2520015T3 (es) * 2005-04-08 2014-11-11 Pfizer Products Inc. [3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
UA94615C2 (uk) * 2006-06-28 2011-05-25 Амген Інк. Інгібітори транспортера-1 гліцину

Also Published As

Publication number Publication date
DK2603219T3 (da) 2014-10-13
TW201211019A (en) 2012-03-16
MX2013001166A (es) 2013-03-22
ZA201300434B (en) 2013-09-25
PL2603219T3 (pl) 2015-03-31
EP2603219A1 (en) 2013-06-19
CL2013000378A1 (es) 2013-05-03
AU2011288536A1 (en) 2013-01-31
SI2603219T1 (sl) 2014-12-31
AR084401A1 (es) 2013-05-15
CY1115886T1 (el) 2017-01-25
CR20130027A (es) 2013-03-04
PE20131100A1 (es) 2013-09-23
KR101455947B1 (ko) 2014-10-28
MA34457B1 (fr) 2013-08-01
CN103068388A (zh) 2013-04-24
JP2013533297A (ja) 2013-08-22
NZ604891A (en) 2015-01-30
WO2012019970A1 (en) 2012-02-16
PH12013500078A1 (en) 2013-03-11
CA2803656A1 (en) 2012-02-16
KR20130045379A (ko) 2013-05-03
EP2603219B1 (en) 2014-09-17
ECSP13012431A (es) 2013-03-28
PT2603219E (pt) 2014-11-25
SG187108A1 (en) 2013-02-28
AU2011288536B2 (en) 2014-10-09
EA201291477A1 (ru) 2013-06-28
BR112013003068A2 (pt) 2016-06-28
US20120035156A1 (en) 2012-02-09
HRP20141199T1 (hr) 2015-02-13

Similar Documents

Publication Publication Date Title
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
ES2624795T3 (es) Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
GEAP202115066A (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
AR092955A1 (es) Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
MX2012013907A (es) Compuestos heteroarilo nitrogenados.
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
CR20120410A (es) Pirrolidina-2-carboxamidas sustituidas
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
AR066659A1 (es) Derivados de espiroindolinona
CR20120418A (es) Inhibidores de virus flaviviridae
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
PE20160995A1 (es) Inhibidores de syk
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
CR20110099A (es) Pirrolidina-2-carboxamidas sustituidas
AR075243A1 (es) Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции